Quarterly report pursuant to Section 13 or 15(d)

Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details)

v3.23.1
Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue $ 12,674 $ 5,897
Collaboration and License Agreements and Supply Agreements    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 12,674 5,897
Collaboration and License Agreements and Supply Agreements | Bristol-Myers Squibb Company ("BMS")    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 3,166 2,165
Collaboration and License Agreements and Supply Agreements | Merck Sharp & Dohme Corporation ("Merck")    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 2,553 1,064
Collaboration and License Agreements and Supply Agreements | Merck KGaA, Darmstadt, Germany (operating in the United States and Canada under the name ''EMD Serono'')    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 8 1,897
Collaboration and License Agreements and Supply Agreements | Astellas Pharma Inc. ("Astellas")    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 6,272  
Collaboration and License Agreements and Supply Agreements | Vaxcyte    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 675 771
BMS Agreement and the 2018 BMS Master Services Agreement    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Revenues 3,166 2,165
BMS Agreement and the 2018 BMS Master Services Agreement | Research and Development Services    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Revenues 221 244
BMS Agreement and the 2018 BMS Master Services Agreement | Materials Supply    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Revenues 2,945 1,921
2020 Merck Master Services Agreement    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 2,553 1,064
2020 Merck Master Services Agreement | Ongoing Performance Related to Unsatisfied Performance Obligations    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue   862
2020 Merck Master Services Agreement | Research and Development Services    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 125 173
2020 Merck Master Services Agreement | Materials Supply    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 2,428 29
2019 EMD Serono Supply Agreement    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 8 1,897
2019 EMD Serono Supply Agreement | Research and Development Services    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 6 284
2019 EMD Serono Supply Agreement | Materials Supply    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 2 1,613
Supply Agreement | Vaxcyte    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 675 771
Supply Agreement | Vaxcyte | Research and Development Services    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 504 601
Supply Agreement | Vaxcyte | Materials Supply    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 171 $ 170
Astellas License and Collaboration Agreement    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 6,272  
Astellas License and Collaboration Agreement | Ongoing Performance Related to Unsatisfied Performance Obligations    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 2,572  
Astellas License and Collaboration Agreement | Research and Development Services    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 1,157  
Astellas License and Collaboration Agreement | Financing Component on Unearned Revenue    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue $ 2,543